

Betaalbaarheid van technologie in preventieve gezondheidszorg

David Smeets
Digital Health & Data Policy Manager
26 November
Antwerp
We are days

Johnson & Johnson
Innovative Medicine

©Janssen-Cilag NV, a Johnson & Johnson company - CP- 555062- Approval date: 11-2025 – vu/er Luc Van Oevelen, Antwerpseweg 15-17, 2340 Beerse

Preventie in BE

1,8 %

van de Belgische
gezondheidsuitgaven ging naar
preventie

3,4 %

OESO – gemiddelde

Finland (4,6 %)

Canada (6,9 %)

5 %

Minimum voor toekomst die
gezondheidsexperts vooropstellen

Wereldgezondheidsorganisatie
aanbeveling

Pilot Learnings

Chronische lymfatische leukemie

Empowering CLL patients through telemonitoring: insights from a Belgian Pilot



Personal We Are




Weight

Heart rate




Activity

data




CITIZEN-CENTRIC APPROACH



Societal costs of depression and outcomes of care in Finland

Figure 1: Patient status over the follow-up period according to service use



Data labels are reported as 'outcome category' year: number of patients. The 5-year outcomes (shown in the right-most column) were categorised as follows, from 'worst' to 'best' outcome: 1) death, 2) requiring social services, 3) requiring inpatient care, 4) having continuous social benefits, 5) taking sick leave,^a 6) requiring specialised outpatient care, 7) requiring primary outpatient care, and 8) not using any services or benefits (healthy). For a given calendar year, each patient was assigned a status based on the 'worst' outcome they experienced. ^aSick leave was defined as a period longer than 10 days but shorter than 300 days.

- Globally, an estimated 12 billion working days are lost annually to depression and anxiety, costing US\$ 1 trillion/year in lost productivity.¹
- Helsinki University Hospital (HUS) Department of Psychiatry is currently moving toward value-based healthcare; this study assessed the current outcomes and costs of care to inform decision making on resource allocation.
- Here, preliminary results of this assessment are presented.

REFERENCES

1. World Health Organisation (WHO). Mental health at work [Fact sheet]. 2024. <https://www.who.int/news-room/fact-sheets/detail/mental-health-at-work> (Last accessed 13 September 2024);
2. Helsinki: The Finnish Medical Society Duodecim. Depression. Current Care Guidelines. 2024. <https://www.kaypahoito.fi/hoi50023> (Last accessed 13 September 2024).

J&J Innovative Medicine

Naar een gealigneerde aanpak met duidelijke visie

Uitdagingen en oplossingen

Huidige middelen worden erg gefragmenteerd aangewend zonder een duidelijke en gerichte strategie. Investerings kunnen zichzelf terugverdienen.

Van kost naar return on investment

- Strategische overheidsinvesteringen + PPS :
fundament voor transformatie
- Fragmentatie van financiering

Preventie(regionaal) VS behandelingen (federaal)

- Schaalvergroting / Vergoedingsmechanisme
- Digitale kloof
- Outcome based segmentatie model/ VBHC contracten

❖ **Systeem denken**

❖ **Segmentatie**

❖ **Service design**

Thank you



If you have more questions, please contact:
David Smeets
dsmeets1@its.jnj.com

Johnson & Johnson
Innovative Medicine